If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
  Australasian PsychiatryVolume 12 Issue 4, Pages 369 - 375 Published Online: 9 Dec 2004 2006 Royal Australian and New Zealand College of Psychiatrists
Abstract | References | Full Text: HTML, PDF (Size: 118K) | Related Articles | Citation Tracking  ATTENTION-DEFICIT HYPERACTIVITY DISORDER Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder Philip Hazell Professor, University of Newcastle and Director, Child and Youth Mental Health Service, Wallsend Hospital, Hunter-New England Mental Health Service, Newcastle, NSW, Australia. Copyright 2004 Blackwell Science Asia Pty Ltd KEYWORDS adrenergic uptake inhibitors • attention deficit disorder with hyperactivity • delayed-action preparations • methylphenidate ABSTRACTObjective: To examine the pharmacodynamic and pharmacokinetic properties, efficacy, safety and cost of Ritalin LA, Concerta and Strattera, three compounds recently released in Australia for the treatment of attention-deficit hyperactivity disorder (ADHD). Methods: MEDLINE was searched for relevant review articles and primary treatment studies. Data were augmented by product information supplied by the respective manufacturers. Costing information was obtained by surveying five community pharmacy outlets in Newcastle-Lake Macquarie, New South Wales. Results: The three compounds reviewed have similar tolerability and efficacy to immediate-release methylphenidate, with the advantage of once daily dosing. The properties of these agents, particularly Strattera, make them less able to be abused. Ritalin LA may be superior to Concerta in controlling symptoms of ADHD in the first 4 h following ingestion, but the data should be interpreted with caution. Conclusions: The newer treatments for ADHD offer advantages over immediate-release methyphenidate in dosing schedule and duration of action that may be of particular benefit to adolescent and adult patients. Prescription of these medications may be limited by their expense to the patient. |  |
